Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) FCF Margin (2020 - 2025)

Insight Molecular Diagnostics' FCF Margin history spans 6 years, with the latest figure at 2135.38% for Q3 2025.

  • For Q3 2025, FCF Margin rose 274896.0% year-over-year to 2135.38%; the TTM value through Sep 2025 reached 543.71%, up 232343.0%, while the annual FY2024 figure was 1128.6%, 44199.0% up from the prior year.
  • FCF Margin for Q3 2025 was 2135.38% at Insight Molecular Diagnostics, down from 1279.54% in the prior quarter.
  • Across five years, FCF Margin topped out at 671.59% in Q4 2022 and bottomed at 18291.04% in Q3 2022.
  • The 5-year median for FCF Margin is 1279.54% (2025), against an average of 2519.27%.
  • The largest annual shift saw FCF Margin soared 4226259bps in 2021 before it crashed -1713485bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 384.85% in 2021, then skyrocketed by 75bps to 671.59% in 2022, then crashed by -322bps to 1492.99% in 2023, then soared by 75bps to 376.11% in 2024, then tumbled by -468bps to 2135.38% in 2025.
  • Per Business Quant, the three most recent readings for IMDX's FCF Margin are 2135.38% (Q3 2025), 1279.54% (Q2 2025), and 288.35% (Q1 2025).